Updated

Updated · SciTechDaily · Jul 10

Oregon State Researchers Lift Glioblastoma Survival 50% in Mice With Mannose-Coated Nanoparticles

Updated

Updated · SciTechDaily · Jul 10

Oregon State Researchers Lift Glioblastoma Survival 50% in Mice With Mannose-Coated Nanoparticles

Q: This sugar-coated 'Trojan horse' beat brain cancer in mice. When could human trials begin?

There is no announced date for human trials yet, and they are unlikely to start immediately. The Oregon State treatment is still at the preclinical stage, with results so far limited to mice. The study is promising: the mannose-coated lipid nanoparticles crossed the blood-brain barrier, targeted glioblastoma cells with high GLUT1 activity, delivered mRNA encoding the tumor-suppressor PTEN, shrank tumors, and extended median survival in mice by about 50%, from 33 to 49 days, without measurable organ toxicity. But mouse success is only an early step. Before any human trial can begin, the researchers would typically need more animal data, repeat-dose safety studies, manufacturing work to produce the nanoparticles under clinical-grade standards, and regulatory clearance to file for a first-in-human study. That process usually takes years rather than months, especially for a new brain-targeted mRNA nanomedicine. The reporting around the study says only that the therapy will require years of additional safety and efficacy testing before it could reach patients. In practical terms, if follow-up studies continue to go well, an early Phase 1 trial could potentially be considered within the next few years, but no formal timeline has been given by Oregon State or in the published paper. So the short answer is: not yet, and probably not soon. Human testing remains a future possibility, not a scheduled next step.

3 articles · Updated · SciTechDaily · Jul 10

Median survival in mice with glioblastoma rose 50% after Oregon State researchers used sugar-coated lipid nanoparticles to deliver tumor-suppressing mRNA across the blood-brain barrier.
Mannose on the nanoparticle surface exploited the brain's GLUT1 transporter, and chemically linking mannose to cholesterol increased surface coverage sixfold to help the particles compete with blood glucose.
Glioblastoma cells express GLUT1 at about three times normal brain levels, helping the particles accumulate in tumors, where the mRNA restored the PTEN tumor suppressor and produced tumor shrinkage without measurable organ toxicity.
The findings remain preclinical, but they target two central obstacles in glioblastoma treatment: getting drugs into the brain and concentrating them in tumor tissue.
Glioblastoma affects 3.19 people per 100,000 in the United States, and more than 95% of patients die within five years, underscoring the need for new delivery strategies.

Sources

SciTechDaily7d ago

Oregon State Researchers Increase Glioblastoma Survival by 50% Using Sugar-Coated Nanoparticles in Mice

Yahoo! Voices7d ago

Nanoparticles Cross Blood-Brain Barrier in Mice to Shrink Deadly Glioblastoma

ScienceDaily15h ago

This sugar-coated therapy boosted survival against deadly brain cancer by 50% in mice | ScienceDaily

This sugar-coated 'Trojan horse' beat brain cancer in mice. When could human trials begin?

Could brain cancer outsmart this new therapy by simply changing its metabolic 'diet'?

This nanoparticle crossed the brain's 'impenetrable' wall. Could it be the key to treating Alzheimer's next?

50% Survival Increase in Mouse Glioblastoma: Oregon State’s Mannose-Functionalized mRNA Nanoparticle Therapy Sets New Benchmark

Overview

Oregon State University researchers have introduced a groundbreaking strategy to tackle glioblastoma, a highly aggressive brain cancer. Their approach addresses two major challenges: the difficulty of delivering treatments across the blood-brain barrier and the need to target tumor cells precisely without harming healthy brain tissue. By developing advanced delivery systems, the OSU team aims to navigate these barriers and improve therapy effectiveness. This innovative work represents a significant step forward in overcoming persistent obstacles in glioblastoma treatment, offering new hope for patients facing this devastating disease.

...